S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
PASG · Passage Bio, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
$3.66
-0.87
(-19.21%)
● At close: October 13 at 4:00:00 PM EDT
DAY'S RANGE
$3.66
$3.66
$3.66
52-WEEK RANGE
$3.66
$3.29
$20.00
What's happening
- PASG is down 19.21% today, trading at $3.66. — Live quote
- It's trading within 3% of its 52-week low ($3.29). (Finnhub fundamentals)
- Volume today (480) is well below its 3-month average of 52,730. (Finnhub fundamentals)
- Reports earnings on 2026-11-09, 18 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-2.44 actual vs. $-2.70 estimated (+9.6%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 2
Buy 4
Hold 3
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (9 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
PASG
-69.49%
vs S&P 500
-82.27%
1-YEAR RETURN
PASG
-57.85%
vs S&P 500
-72.41%
6-MONTH RETURN
PASG
-69.18%
3-MONTH RETURN
PASG
-26.68%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-2.44
Est. $-2.70
BEAT +9.6%
2026-04-26 (Q1 2026)
$-2.16
Est. $-2.85
BEAT +24.1%
2026-01-26 (Q4 2025)
$-3.95
Est. $-2.62
MISS -50.7%
2025-10-26 (Q3 2025)
$-2.44
Est. $-2.86
BEAT +14.6%
Valuation Measures & Ratios
Enterprise Value4-$12.6M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)—
Price / Book73.52
EV4 / Revenue—
EV4 / EBITDA—
Profit Margin—
Operating Margin—
Return on Equity (ROE8)-218.59%
Return on Assets (ROA9)-72.92%
Avg Volume (3M)52,730
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $15.6M | $23.3M | $25.5M | $25.0M | $22.8M |
| P/E | -0.48 | -0.58 | -0.49 | -0.42 | -0.34 |
| Price/Book | 3.50 | 1.99 | 0.82 | 0.65 | 0.49 |
| EV/EBITDA | 0.24 | 0.23 | 0.50 | — | — |
| ROE | -729.67% | -341.20% | -166.71% | -157.15% | -144.41% |
| ROA | -129.15% | -109.97% | -69.96% | -75.91% | -78.42% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short90,840
Change from Prior Settlement-6.36%
% of Float—
Days to Cover (Short Ratio)3.67
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 8-K, filed 2026-09-03; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Trailing 52-week price return is -57.8%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on PASG
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Operating income | -$8.3M | -$8.2M | -$8.7M | -$10.3M | -$16.5M | -$20.7M | -$17.4M | -$18.1M |
| Net income | -$7.8M | -$7.6M | -$7.7M | -$9.4M | -$15.4M | -$19.3M | -$16.0M | -$16.7M |
| EPS (diluted) | $-2.44 | $-2.36 | $-2.44 | $-2.96 | $-4.87 | $-6.15 | $-5.09 | $-0.30 |
| EPS (basic) | $-2.44 | $-2.36 | $-2.44 | $-2.96 | $-4.87 | $-6.15 | $-5.09 | $-0.30 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $25.2M | $36.5M | $62.3M | $74.2M | $79.2M | $86.0M | $102.4M | $111.8M |
| Total liabilities | $20.7M | $24.7M | $43.5M | $43.0M | $40.9M | $39.3M | $41.2M | $39.0M |
| Stockholders' equity | $4.5M | $11.8M | $18.8M | $31.1M | $38.3M | $46.7M | $61.3M | $72.7M |
| Total current assets | $25.2M | $34.7M | $47.8M | $55.7M | $60.3M | $66.7M | $78.8M | $87.2M |
| Total current liabilities | $20.7M | $20.1M | $23.1M | $22.2M | $19.8M | $17.8M | $19.4M | $17.0M |
| Cash & equivalents | $24.2M | $33.3M | $46.3M | $52.8M | $57.6M | $63.4M | $37.6M | $32.3M |
| Property, plant & equipment | — | $826.0K | $4.1M | $5.2M | $5.3M | $5.5M | $9.3M | $10.0M |
| Other non-current assets | — | $244.0K | $244.0K | $270.0K | $270.0K | $274.0K | $463.0K | $463.0K |
| Accounts payable | $902.0K | $1.3M | $1.1M | $952.0K | $2.4M | $1.5M | $742.0K | $1.5M |
| Deferred revenue (current) | $16.2M | $13.8M | $13.8M | $13.8M | $9.7M | $8.7M | $8.2M | $5.0M |
| Other current liabilities | — | — | — | — | — | — | — | — |
| Other non-current liabilities | — | — | — | — | — | — | — | — |
| Common stock & paid-in capital | — | — | — | — | — | $6.0K | $6.0K | $6.0K |
| Retained earnings | -$720.1M | -$712.3M | -$704.8M | -$691.8M | -$684.0M | -$674.6M | -$659.2M | -$646.5M |
| Accumulated other comprehensive income (loss) | — | — | — | — | — | — | $8.0K | $32.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$9.2M | -$13.0M | -$6.5M | -$4.9M | -$6.3M | -$13.8M | -$8.4M | -$7.4M |
| Investing cash flow | $0 | $20.0K | $0 | $0 | $585.0K | $39.6M | $13.7M | $15.0M |
| Financing cash flow | — | — | $9.0K | $0 | $14.0K | — | $47.0K | $0 |
| Depreciation & amortization | $25.0K | $129.0K | $527.0K | $200.0K | $200.0K | $201.0K | $2.3M | $800.0K |
| Share-based compensation | $525.0K | $556.0K | $609.0K | $611.0K | $923.0K | $858.0K | $1.2M | $1.4M |
| Purchases of investments | — | — | — | — | — | — | $15.6M | $21.8M |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating income | -$49.3M | -$70.4M | -$108.4M | -$138.4M | -$185.7M |
| Net income | -$45.5M | -$64.8M | -$102.1M | -$136.1M | -$185.4M |
| EPS (diluted) | $-14.35 | $-21.04 | $-1.86 | $-2.50 | $-3.48 |
| EPS (basic) | $-14.35 | $-21.04 | $-1.86 | $-2.50 | $-3.48 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $62.3M | $102.4M | $150.5M | $243.5M | $355.1M |
| Total liabilities | $43.5M | $41.2M | $39.3M | $42.2M | $36.4M |
| Stockholders' equity | $18.8M | $61.3M | $111.3M | $201.4M | $318.7M |
| Total current assets | $47.8M | $78.8M | $118.0M | $197.0M | $325.1M |
| Total current liabilities | $23.1M | $19.4M | $16.3M | $18.4M | $29.5M |
| Cash & equivalents | $46.3M | $37.6M | $21.7M | $34.6M | $129.0M |
| Property, plant & equipment | $4.1M | $9.3M | $15.3M | $22.5M | $23.8M |
| Other non-current assets | $244.0K | $463.0K | $433.0K | $4.3M | $6.2M |
| Accounts payable | $1.1M | $742.0K | $1.3M | $4.1M | $9.4M |
| Deferred revenue (current) | $13.8M | $8.2M | — | — | — |
| Other current liabilities | — | — | $2.0M | — | $500.0K |
| Other non-current liabilities | — | — | — | — | — |
| Common stock & paid-in capital | — | $6.0K | $5.0K | $5.0K | $5.0K |
| Retained earnings | -$704.8M | -$659.2M | -$594.5M | -$492.4M | -$356.3M |
| Accumulated other comprehensive income (loss) | — | $8.0K | -$43.0K | -$966.0K | -$413.0K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$31.5M | -$48.0M | -$78.3M | -$118.2M | -$126.9M |
| Investing cash flow | $40.2M | $54.9M | $65.2M | $25.2M | -$45.8M |
| Financing cash flow | $23.0K | $8.9M | $135.0K | -$1.4M | $166.7M |
| Depreciation & amortization | $728.0K | $3.1M | $3.7M | $3.7M | $1.5M |
| Share-based compensation | $3.0M | $5.8M | $10.9M | $19.0M | $32.7M |
| Purchases of investments | — | $88.2M | $129.4M | $157.8M | $202.5M |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding PASG as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-04-15 to 2026-06-25
Recent transactions
- Insiders have net bought 50,055 shares over the last 182 days, across 1 purchase and 0 sales.
- Most recent: Lynx1 Capital Management LP (10% owner) — Open market purchase of 50,055 shares on 2026-06-25.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)50,055 sh(1 txns)
Sales (open market)0 sh(0 txns)
Net Shares+50,055
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Lynx1 Capital Management LP | 10% owner | Open market purchase | 2026-06-25 | 50,055 |
| Chou William | PRESIDENT AND CEO | Option exercise | 2026-01-08 | 10,000 |
| Borthwick Kathleen | CFO | Option exercise | 2026-01-08 | 5,000 |
| ORBIMED ADVISORS LLC | 10% owner | Open market sale | 2025-06-26 | 213,257 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-06-25 | Lynx1 Capital Management LP | 10% owner | Open market purchase | 50,055 | $4.12 |
| 2026-01-08 | Chou William | PRESIDENT AND CEO | Option exercise | 10,000 | — |
| 2026-01-08 | Chou William | PRESIDENT AND CEO | Open market sale | 4,076 | $18.44 |
| 2026-01-08 | Borthwick Kathleen | CFO | Option exercise | 5,000 | — |
| 2026-01-08 | Borthwick Kathleen | CFO | Open market sale | 2,062 | $18.44 |
| 2025-09-15 | Lynx1 Capital Management LP | 10% owner | Open market purchase | 11,900 | $6.99 |
| 2025-09-12 | Lynx1 Capital Management LP | 10% owner | Open market purchase | 19,783 | $6.99 |
| 2025-09-11 | Lynx1 Capital Management LP | 10% owner | Open market purchase | 325 | $6.96 |
| 2025-07-24 | Lynx1 Capital Management LP | 10% owner | Open market purchase | 66,423 | $5.71 |
| 2025-07-23 | Lynx1 Capital Management LP | 10% owner | Open market purchase | 49,302 | $5.74 |
| 2025-07-22 | Lynx1 Capital Management LP | 10% owner | Open market purchase | 13,123 | $5.44 |
| 2025-06-26 | ORBIMED ADVISORS LLC | 10% owner | Open market sale | 213,257 | $0.33 |
| 2025-06-25 | ORBIMED ADVISORS LLC | 10% owner | Open market sale | 138,800 | $0.33 |
| 2025-06-24 | ORBIMED ADVISORS LLC | 10% owner | Open market sale | 231,600 | $0.35 |
| 2025-04-24 | ORBIMED ADVISORS LLC | 10% owner | Open market sale | 68,195 | $0.32 |
| 2025-04-23 | ORBIMED ADVISORS LLC | 10% owner | Open market sale | 89,328 | $0.34 |
| 2025-04-22 | ORBIMED ADVISORS LLC | 10% owner | Open market sale | 78,049 | $0.34 |
| 2025-04-17 | ORBIMED ADVISORS LLC | 10% owner | Open market sale | 77,090 | $0.33 |
| 2025-04-16 | ORBIMED ADVISORS LLC | 10% owner | Open market sale | 61,638 | $0.33 |
| 2025-04-15 | ORBIMED ADVISORS LLC | 10% owner | Open market sale | 10,326 | $0.38 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 06:45 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-09-03 | 8-K | 2026-09-02 | View on SEC.gov → |
| 2026-08-10 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-06-29 | 4 | 2026-06-25 | View on SEC.gov → |
| 2026-06-24 | 8-K | 2026-06-23 | View on SEC.gov → |
| 2026-05-27 | 8-K | 2026-05-21 | View on SEC.gov → |
| 2026-05-26 | 8-K | 2026-05-19 | View on SEC.gov → |
| 2026-05-21 | 4 | 2026-05-19 | View on SEC.gov → |
| 2026-05-21 | 4 | 2026-05-19 | View on SEC.gov → |
| 2026-05-21 | 4 | 2026-05-19 | View on SEC.gov → |
| 2026-05-21 | 4 | 2026-05-19 | View on SEC.gov → |
| 2026-05-21 | 4 | 2026-05-19 | View on SEC.gov → |
| 2026-05-21 | 4 | 2026-05-19 | View on SEC.gov → |
Recent news
Headlines about PASG (Passage Bio, Inc.). Links open the publisher — we don’t host full articles.
-
EQUITY ALERT: The M&A Class Action Firm Is Investigating the Merger — UTZ, SAFT, PASG and FNWD - IS IT A FAIR DEAL FOR YOU?
Morningstar · 2026-10-21 -
Passage Bio, Inc. (Nasdaq – PASG), American Oncology Network, Inc. (OTCQX – AONC), Utz Brands, Inc. (NYSE
StreetInsider · 2026-10-21 -
PASG Stock Alert: Halper Sadeh LLC is Investigating Whether Passage Bio, Inc. is Obtaining a Fair Price for its Shareholders - Carroll County Mirror-Democrat
Carroll County Mirror-Democrat · 2026-10-21 -
PASG Stock Alert: Halper Sadeh LLC is Investigating Whether Passage Bio, Inc. is Obtaining a Fair Price for its Shareholders
Business Wire · 2026-10-21 -
Passage Bio amends merger terms: what it means for Passage Bio stock
AD HOC NEWS · 2026-10-21 -
Passage Bio outlines USD 100.0 million financing for Passage Bio stock
AD HOC NEWS · 2026-10-16 -
Remix to go public in reverse merger with once high-flying Passage Bio
Yahoo Finance · 2026-06-25 -
Passage Bio, Inc. (PASG) M&A Call Prepared Remarks Transcript
Seeking Alpha · 2026-06-25
No headlines in this category right now — try “All”.